Animal experiments
Rats received sunitinib (sunitinib malate, LC Laboratories, Woburn, MA, USA) at 15 mg/(kg*d) or vehicle for four days as described above. On day five, animals were anesthetized with pentobarbital (60 mg/kg, i.p.) and instrumented with a carotid artery catheter for arterial pressure recordings and blood sampling and a jugular vein catheter for intravenous infusion of isotonic saline containing 4 mg/ml inulin and 10 mg/ml bovine serum albumin. The infusion rate was 1.2 ml/(h*100 g body weight). Rats were further instrumented with a tracheal cannula for artificial ventilation and a femoral vein catheter for administration of pentobarbital [20 mg/(kg*h)], pancuronium bromide [1 mg/(kg*h)] and L-NAME. Urine was sampled via ureter catheters and renal blood flow (RBF) was recorded with an ultrasound transit time flow-meter (Transonic Systems, Ithaca, NY) placed around the left renal artery. A fine polyethylene catheter was inserted into the left femoral artery and its bent tip advanced to the branching point of the left renal artery from the aorta 1, 3 . This catheter served for intrarenal drug administration and was continuously perfused with isotonic saline at 3 µl/min, when no drugs were given. Exact catheter placement was verified by a fall in RBF in response to acetylcholine (17 ng, i.a.) without effects on systemic arterial pressure.
For experiments involving intrarenal artery L-NAME administration animals were additionally instrumented with a Laser-Doppler flow probe which was advanced into the renal medulla of the left kidney with the aid of a stereotaxic apparatus (David Kopf, Instruments, Tujunga, CA) and coupled to a Laser-Doppler flowmeter (Perimed, Järfälla, Sweden). To prevent movement artifacts, the left kidney was placed in a plastic kidney holder and covered with gauze soaked with isotonic saline. Urine flow was measured gravimetrically. At the end of each clearance period, 500 µl of arterial blood were sampled. Sodium and inulin concentrations were measured in plasma and urine and the data were used to calculate glomerular filtration rate (GFR) and fractional sodium excretion FENa 1 . Acetylcholine, N-nitro-L-arginine methyl ester (L-NAME) and inulin were from Sigma Aldrich, Munich, Germany.
Experiment 1 (intravenous L-NAME):
After a 45 min postsurgical equilibration period, a dose-response curve on the effect of acetylcholine on renal vascular resistance (RVR) was obtained. Acetylcholine was administered via the renal artery at increasing doses that caused minimal effects on systemic arterial pressure (blood pressure reductions less than 10 mmHg). Depending on the dose, acetylcholine administration lasted between 2.5 and 10s which resulted in a sudden rise in RBF. Thereafter, GFR and FENa were measured over a 30min clearance period. This period was followed by intravenous administration of the non-selective NOS inhibitor L-NAME at 10 mg/kg 4 .
After another 30 min, the protocol was repeated (Fig. S1 ). At the end of the experiments, the animals were killed with an overdose of pentobarbital and the kidneys were removed, blotted and weighed.
Experiment 2 (intrarenal artery L-NAME):
To test whether NO differentially contributes to the regulation of FENa and renal medullary blood flow (RMF) in control and sunitinibtreated animals, baseline data on renal hemodynamics and FENa were obtained during a 30 min clearance period that was started after 45 min of postsurgical equilibration.
Thereafter, L-NAME was administered at 250 µg/kg via the renal artery catheter (infusion rate: 5 µg L-NAME/min). We opted for this L-NAME dose and this route of administration to selectively inhibit renal NOS with minimal systemic effects that could counteract the effects of NOS inhibition on FENa 5, 6 . Thereafter, renal hemodynamic parameters and FENa were measured for another 30 min (Fig. S1 ). At the end of the experiments, animals were killed with an overdose of pentobarbital and the kidneys were removed, blotted and weighed. Side-specific NOS inhibition was verified by renal function parameters that were obtained simultaneously from both kidneys during L-NAME infusion into the left renal artery (Fig. S2 ).
Blood pressure response to cinaciguat
At the age of ten weeks, rats were implanted with radiotelemetric devices (HD-S10, DSI-Transoma Medical, St Paul, MN). After one week of recovery, arterial pressure and heart rate recordings were started. After two days of recording baseline data, animals were placed on a sunitinib-containing diet [15 mg/(kg*d)] for four days and randomized to two protocols. Group I continued to receive sunitinib [15 mg/(kg*d)] only, whereas group II received the soluble guanylate cyclase (sGC) activator cinaciguat [BAY 58-2667, 10 mg/(kg*d) for one day] in addition to sunitinib with the diet.
Cinaciguat was kindly provided by Bayer AG Pharmaceuticals Division, Leverkusen, Germany. Pilot studies conducted prior to this experiment had revealed that the combined administration of sunitinib and cinaciguat for more than one day was not well tolerated by the animals leading to decreased food and hence drug intake. The effects on food intake were already evident after 24h, when ingestion was reduced by 20-30 per cent. To control for these effects, we opted for a pair feeding design with rats in group I receiving the same amount of food that had been ingested by the rats in group II.
Chemical analyses
Plasma and urine samples were analyzed for inulin and Na + concentrations as described previously 1, 3 . GFR and FENa were calculated according to standard formulas. Urinary nitrite concentrations were determined by diazo dye formation and urinary and plasma nitrate concentrations were determined enzymatically via the nitrate reductase reaction with a test kit from R-Biopharm, Darmstadt, Germany following the manufacturer's instructions. Diazo dye and NADPH concentrations were measured spectrophotometrically. Nitrite and nitrate concentrations (NOx) were added and 24h renal NOx excretion was calculated from NOx concentration and 24h urine volume. The detection limit of the nitrate reductase reaction for nitrate was 2 µmol/l. Urinary cGMP concentrations were measured using a competitive ELISA with acetylcholine esterase-conjugated cGMP as tracer (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's instructions. Urine samples were collected in metabolism cages and kept frozen at -20°C until analyzed. Samples were diluted at 1:1000 for analyses. Twenty-four-hour cGMP excretion rates were calculated from the cGMP urine concentrations and urinary excretion rates and normalized to 100 g body weight.
Renal mRNA and protein abundances
Tissues were obtained from rats treated with sunitinib at 15 mg/(kg*d) or vehicle for four days. Kidneys were dissected into cortex and medulla. Samples were frozen in liquid nitrogen and stored at -70°C until further analyses. Figure S1 . Sequence of interventions in acute experiments on renal function in anesthetized animals (experiments 1 and 2). Ach: acetylcholine Figure S2 . Renal function data from both kidneys obtained after L-NAME administration to the left kidney.
Glomerular filtration rate (GFR), natriuresis (UNaV) and diuresis measured simultaneously in the left kidney (L), which was infused with L-NAME via the renal artery at 250 µg/kg and in the right kidney (R) which did not receive L-NAME. White bars: Control animals. Shaded bars: Sunitinib-treated animals. (n = 10 per group) * p< 0.05 
